Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937377 | 0.93 | PDE4B (0.70) | PDE4BMAPK1PDE4D | |
| SCHEMBL4938117 | 0.93 | PDE4B (0.69) | PDE4BMAPK1PDE4D | |
| SCHEMBL4330493 | 0.91 | PDE4B (0.73) | PDE4BMAPK1PDE4D | |
| SCHEMBL4934740 | 0.90 | PDE4B (0.59) | PDE4BMAPK1 | |
| SCHEMBL4934304 | 0.89 | PDE4B (0.71) | PDE4BMAPK1PDE4D | |
| SCHEMBL4930318 | 0.89 | PDE4B (0.57) | PDE4BPDE4D | |
| SCHEMBL4939009 | 0.88 | PDE4B (0.69) | PDE4BPDE4D | |
| SCHEMBL4930708 | 0.88 | PDE4B (0.69) | PDE4BMAPK1PDE4D | |
| SCHEMBL1435171 | 0.87 | PDE4B (0.66) | PDE4BMAPK1PDE4D | |
| SCHEMBL8281071 | 0.86 | PDE4B (0.62) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | claimed |
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| EP-1751151-A1 | PYRAZOLO '3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005090348-A1 | PYRAZOLO ’3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | PDE4A, PDE4B, PDE3B | PDE4B 2/4885KDM4E 392/4885L3MBTL1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.